Trametinib
| Overview | |
| Catalog # | bs-83007c-10-mg |
| Product Name | Trametinib |
| Specifications | |
| Storage Buffer | Off-white of pale pink solid |
| Storage Condition | -20°C |
| Target | |
| Product Information | Trametinib is a highly potent (IC50 uMEK1 = 0.7 nM, pp-MEK1 = 14.9 nM)1 and selective MEK inhibitor displaying selective inhibition of proliferation in various BRAF mutant cancer cell lines (IC50 ACHN = 9.8 nM; IC50 HT-29 = 0.57 nM)2. It is approved for use against unresectable or metastatic BRAF-mutant melanoma alone or in combination with Dabrafenib. Trametinib can limit outgrowth of tumors without directly inhibiting tumor cell proliferation via abrogation of cytokine-driven expansion of monocytic myeloid-derived suppressor cells (mMDSC) through a mechanism involving CD8+ T cells.3,4 Trametinib also displays potent anti-arthritic effects.5 |
| Description | CAS Number: 871700-17-3 Chemical Name: N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide Molecular weight: 615.39 Formula: C26H23FIN5O4 Solubility: DMSO (20 mg/ml, warm) Physical Properties: White solid Purity: 98% by TLC/HPLC NMR (Conforms) |
Powered by Bioz